Table 3.
Timing | Tumor characteristics | Nerve-sparing | Hormone therapy | |||||
---|---|---|---|---|---|---|---|---|
r p-value |
Age at RP | Follow-up duration | Age at follow-up | PSA | T-stage | Gleason score | ||
UF | / | / |
-0.609 0.024 |
-3.557 0.163 |
-3.103 0.163 |
-2.878 0.072 |
/ |
-5.607 0.056 |
UB | / | / | / | -2.944 0.207 |
-4.161 0.051 |
-2.272 0.125 |
2.774 0.046 |
-3.718 0.189 |
SF | -1.304 0.617 |
-0.229 0.302 |
0.176 0.946 |
-1.104 0.601 |
-4.264 0.024 |
-2.106 0.110 |
3.783 0.004 |
-4.259 0.044 |
SB | / |
0.290 <0.001 |
0.272 0.336 |
/ |
-4.852 0.018 |
/ |
5.101 <0.001 |
-7.205 0.076 |
Significant results (p ≤ 0.05) are in bold.
[UF: urinary function; UB: urinary bother; SF: sexual function; SB: sexual bother; RP: radical prostatectomy. [/: Not included for the multivariate analyses]]